NAGE
Niagen Bioscience, Inc.
Price Chart
Latest Quote
$3.38
-0.03 (-0.88%)
Current Price
| Previous Close | $3.41 |
| Open | $3.37 |
| Day High | $3.44 |
| Day Low | $3.37 |
| Volume | 420,991 |
Stock Information
| Shares Outstanding | 79.64M |
| Total Debt | $2.58M |
| Cash Equivalents | $66.40M |
| Revenue | $130.42M |
| Net Income | $18.64M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $269.20M |
| P/E Ratio | 16.10 |
| EPS (TTM) | $0.21 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $205.94M |
| Sales | $130.42M |
| Income | $18.64M |
| Book/sh | $1.03 |
| Cash/sh | $0.83 |
| Employees | 117 |
Financial Ratios
| Quick Ratio | 3.48 |
| Current Ratio | 4.61 |
| Debt/Eq | 3.13 |
| EPS Growth TTM | 24.80% |
Returns & Margins
| ROA | 7.09% |
| ROE | 27.07% |
| Gross Margin | 64.28% |
| Operating Margin | 5.01% |
| Profit Margin | 14.29% |
Ownership
| Insider Ownership | 29.25% |
| Institutional Ownership | 47.20% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 10.56 |
| P/S | 2.06 |
| P/B | 3.27 |
Analyst Data
| Recommendation | none |
| Target Price | $12.60 |
Technical Indicators
| SMA20 | $3.54 |
| SMA50 | $4.07 |
| SMA200 | $5.92 |
| RSI | 42.00 |
| ATR | 0.1429 |
| Shares Float | 59.57M |
| Short Float | 9.09% |
| Short Ratio | 4.22 |
| Volatility | 2.06 |
| Rel Volume | 0.56 |
Performance History
| Week | -3.98% |
| Month | -10.82% |
| Quarter | -28.24% |
| 6 Months | -48.00% |
| YTD | -45.92% |
| Year | -74.85% |
| 3 Years | +102.40% |
| 5 Years | -66.00% |
| 10 Years | +16.96% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $3.38 | 429,600 |
| 2026-06-22 | $3.41 | 529,600 |
| 2026-06-18 | $3.50 | 952,700 |
| 2026-06-17 | $3.37 | 489,500 |
| 2026-06-16 | $3.43 | 571,600 |
| 2026-06-15 | $3.52 | 555,600 |
| 2026-06-12 | $3.45 | 485,500 |
| 2026-06-11 | $3.43 | 522,400 |
| 2026-06-10 | $3.47 | 550,100 |
| 2026-06-09 | $3.51 | 784,600 |
| 2026-06-08 | $3.37 | 567,400 |
| 2026-06-05 | $3.45 | 771,500 |
| 2026-06-04 | $3.50 | 580,900 |
| 2026-06-03 | $3.44 | 634,800 |
| 2026-06-02 | $3.54 | 813,700 |
| 2026-06-01 | $3.61 | 973,600 |
| 2026-05-29 | $3.86 | 1,910,200 |
| 2026-05-28 | $3.84 | 714,500 |
| 2026-05-27 | $3.83 | 1,118,200 |
| 2026-05-26 | $3.86 | 1,398,200 |
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
đ° Latest News
Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications
Insider Monkey âĸ 2026-06-19T18:20:49Z
Niagen Bioscience (NAGE) Stock Sees Split Analyst Revisions As Price Targets Fall
Simply Wall St. âĸ 2026-06-17T13:12:30Z
Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program
Simply Wall St. âĸ 2026-06-05T03:14:21Z
How The Niagen Bioscience (NAGE) Investment Story Is Evolving Without New Analyst Signals
Simply Wall St. âĸ 2026-06-02T15:10:52Z
3 Growth Companies With High Insider Ownership And 15% Revenue Growth
Simply Wall St. âĸ 2026-05-22T11:35:49Z
How The Niagen Bioscience (NAGE) Story Is Shifting As Price Targets Edge Lower
Simply Wall St. âĸ 2026-05-16T00:21:50Z
3 Promising Penny Stocks With Market Caps Over $70M
Simply Wall St. âĸ 2026-05-15T18:05:04Z
Promising Penny Stocks To Consider In May 2026
Simply Wall St. âĸ 2026-05-15T12:05:13Z
Spotlight On Penny Stocks To Consider In May 2026
Simply Wall St. âĸ 2026-05-14T18:05:04Z
May 2026's Promising Penny Stocks
Simply Wall St. âĸ 2026-05-14T12:04:54Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $46,234,000 | $38,011,000 | $32,790,000 | $29,253,000 |
| Cost Of Revenue | $46,234,000 | $38,011,000 | $32,790,000 | $29,253,000 |
| Total Revenue | $129,423,000 | $99,597,000 | $83,570,000 | $72,050,000 |
| Operating Revenue | $129,423,000 | $99,597,000 | $83,570,000 | $72,050,000 |
| Expenses | ||||
| Total Expenses | $115,127,000 | $91,871,000 | $89,169,000 | $90,678,000 |
| Other Income Expense | $1,769,000 | - | - | $2,085,000 |
| Other Non Operating Income Expenses | $-214,000 | - | - | $2,085,000 |
| Net Non Operating Interest Income Expense | $2,127,000 | $1,129,000 | $661,000 | $3,000 |
| Operating Expense | $68,893,000 | $53,860,000 | $56,379,000 | $61,425,000 |
| Selling And Marketing Expense | $35,506,000 | $29,469,000 | $26,438,000 | $28,313,000 |
| General And Administrative Expense | $27,057,000 | $18,375,000 | $24,983,000 | $28,286,000 |
| Total Other Finance Cost | - | - | - | $-3,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $17,382,000 | $8,550,000 | $-4,938,000 | $-16,540,000 |
| Net Interest Income | $2,127,000 | $1,129,000 | $661,000 | $3,000 |
| Interest Income | $2,127,000 | $1,129,000 | $661,000 | $3,000 |
| Normalized Income | $15,488,235 | $8,550,000 | $-4,938,000 | $-16,540,000 |
| Net Income From Continuing And Discontinued Operation | $17,382,000 | $8,550,000 | $-4,938,000 | $-16,540,000 |
| Total Operating Income As Reported | $16,279,000 | $7,726,000 | $-5,599,000 | $-18,628,000 |
| Net Income Common Stockholders | $17,382,000 | $8,550,000 | $-4,938,000 | $-16,540,000 |
| Net Income | $17,382,000 | $8,550,000 | $-4,938,000 | $-16,540,000 |
| Net Income Including Noncontrolling Interests | $17,382,000 | $8,550,000 | $-4,938,000 | $-16,540,000 |
| Net Income Continuous Operations | $17,382,000 | $8,550,000 | $-4,938,000 | $-16,540,000 |
| Pretax Income | $18,192,000 | $8,855,000 | $-4,938,000 | $-16,540,000 |
| Special Income Charges | $1,983,000 | $0 | - | - |
| Interest Income Non Operating | $2,127,000 | $1,129,000 | $661,000 | $3,000 |
| Operating Income | $14,296,000 | $7,726,000 | $-5,599,000 | $-18,628,000 |
| Gross Profit | $83,189,000 | $61,586,000 | $50,780,000 | $42,797,000 |
| Per Share | ||||
| Diluted EPS | $0.20 | $0.11 | $-0.07 | $-0.24 |
| Basic EPS | $0.22 | $0.11 | $-0.07 | $-0.24 |
| Other | ||||
| Tax Effect Of Unusual Items | $89,235 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $13,763,000 | $9,210,000 | $-3,894,000 | $-16,744,000 |
| Total Unusual Items | $1,983,000 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $1,983,000 | $0 | - | - |
| Reconciled Depreciation | $1,450,000 | $1,484,000 | $1,705,000 | $1,884,000 |
| EBITDA (Bullshit earnings) | $15,746,000 | $9,210,000 | $-3,894,000 | $-16,744,000 |
| EBIT | $14,296,000 | $7,726,000 | $-5,599,000 | $-18,628,000 |
| Diluted Average Shares | $85,436,000 | $78,125,000 | $74,985,000 | $69,729,000 |
| Basic Average Shares | $79,178,000 | $75,929,000 | $74,985,000 | $69,729,000 |
| Diluted NI Availto Com Stockholders | $17,382,000 | $8,550,000 | $-4,938,000 | $-16,540,000 |
| Tax Provision | $810,000 | $305,000 | $0 | - |
| Other Special Charges | $-1,983,000 | - | - | - |
| Research And Development | $6,330,000 | $6,016,000 | $4,958,000 | $4,826,000 |
| Selling General And Administration | $62,563,000 | $47,844,000 | $51,421,000 | $56,599,000 |
| Other Gand A | $27,057,000 | $18,375,000 | $24,983,000 | $28,286,000 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $70,873,000 | $45,735,000 | $27,946,000 | $28,001,000 |
| Total Assets | $106,406,000 | $68,278,000 | $54,964,000 | $54,057,000 |
| Total Non Current Assets | $9,600,000 | $4,176,000 | $5,430,000 | $7,490,000 |
| Other Non Current Assets | $425,000 | $368,000 | $383,000 | $497,000 |
| Goodwill And Other Intangible Assets | $5,660,000 | $359,000 | $510,000 | $671,000 |
| Other Intangible Assets | $5,660,000 | $359,000 | $510,000 | $671,000 |
| Current Assets | $96,806,000 | $64,102,000 | $49,534,000 | $46,567,000 |
| Other Current Assets | $1,312,000 | $2,482,000 | $2,450,000 | $2,967,000 |
| Assets Held For Sale Current | $541,000 | $0 | - | - |
| Restricted Cash | $152,000 | $152,000 | $152,000 | $152,000 |
| Inventory | $20,424,000 | $9,192,000 | $14,525,000 | $14,677,000 |
| Receivables | $9,741,000 | $7,768,000 | $5,234,000 | $8,482,000 |
| Accounts Receivable | $9,741,000 | $7,768,000 | $5,234,000 | $8,482,000 |
| Allowance For Doubtful Accounts Receivable | $-147,000 | $-95,000 | $-68,000 | $-122,000 |
| Gross Accounts Receivable | $9,888,000 | $7,863,000 | $5,302,000 | $8,604,000 |
| Cash Cash Equivalents And Short Term Investments | $64,636,000 | $44,508,000 | $27,173,000 | $20,289,000 |
| Cash And Cash Equivalents | $64,636,000 | $44,508,000 | $27,173,000 | $20,289,000 |
| Prepaid Assets | - | - | - | - |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Total Debt | $2,817,000 | $2,651,000 | $3,277,000 | $4,257,000 |
| Long Term Debt And Capital Lease Obligation | $1,815,000 | $1,657,000 | $2,575,000 | $3,561,000 |
| Current Debt And Capital Lease Obligation | $1,002,000 | $994,000 | $702,000 | $696,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $29,873,000 | $22,184,000 | $26,508,000 | $25,385,000 |
| Total Non Current Liabilities Net Minority Interest | $9,954,000 | $4,236,000 | $5,886,000 | $7,516,000 |
| Non Current Deferred Liabilities | $8,139,000 | $2,579,000 | $3,311,000 | $3,955,000 |
| Current Liabilities | $19,919,000 | $17,948,000 | $20,622,000 | $17,869,000 |
| Current Deferred Liabilities | $399,000 | $611,000 | $195,000 | $157,000 |
| Payables And Accrued Expenses | $18,518,000 | $16,343,000 | $19,725,000 | $17,016,000 |
| Payables | $10,796,000 | $8,526,000 | $10,232,000 | $9,679,000 |
| Accounts Payable | $10,796,000 | $8,526,000 | $10,232,000 | $9,679,000 |
| Equity | ||||
| Common Stock Equity | $76,533,000 | $46,094,000 | $28,456,000 | $28,672,000 |
| Total Equity Gross Minority Interest | $76,533,000 | $46,094,000 | $28,456,000 | $28,672,000 |
| Stockholders Equity | $76,533,000 | $46,094,000 | $28,456,000 | $28,672,000 |
| Gains Losses Not Affecting Retained Earnings | $-9,000 | $-4,000 | $-4,000 | $-3,000 |
| Retained Earnings | $-164,528,000 | $-181,910,000 | $-190,460,000 | $-185,493,000 |
| Other | ||||
| Ordinary Shares Number | $79,714,000 | $77,330,000 | $74,981,000 | $74,567,000 |
| Share Issued | $79,714,000 | $77,330,000 | $74,981,000 | $74,567,000 |
| Tangible Book Value | $70,873,000 | $45,735,000 | $27,946,000 | $28,001,000 |
| Invested Capital | $76,533,000 | $46,094,000 | $28,456,000 | $28,672,000 |
| Working Capital | $76,887,000 | $46,154,000 | $28,912,000 | $28,698,000 |
| Capital Lease Obligations | $2,817,000 | $2,651,000 | $3,277,000 | $4,257,000 |
| Total Capitalization | $76,533,000 | $46,094,000 | $28,456,000 | $28,672,000 |
| Foreign Currency Translation Adjustments | $-9,000 | $-4,000 | $-4,000 | $-3,000 |
| Additional Paid In Capital | $240,991,000 | $227,931,000 | $218,845,000 | $214,094,000 |
| Capital Stock | $79,000 | $77,000 | $75,000 | $74,000 |
| Common Stock | $79,000 | $77,000 | $75,000 | $74,000 |
| Non Current Deferred Revenue | $2,674,000 | $2,579,000 | $3,311,000 | $3,955,000 |
| Long Term Capital Lease Obligation | $1,815,000 | $1,657,000 | $2,575,000 | $3,561,000 |
| Current Deferred Revenue | $399,000 | $611,000 | $195,000 | $157,000 |
| Current Capital Lease Obligation | $1,002,000 | $994,000 | $702,000 | $696,000 |
| Current Accrued Expenses | $7,722,000 | $7,817,000 | $9,493,000 | $7,337,000 |
| Net PPE | $3,515,000 | $3,449,000 | $4,537,000 | $6,322,000 |
| Accumulated Depreciation | $-5,754,000 | $-5,764,000 | $-5,410,000 | $-4,554,000 |
| Gross PPE | $9,269,000 | $9,213,000 | $9,947,000 | $10,876,000 |
| Leases | $2,209,000 | $2,209,000 | $2,148,000 | $2,060,000 |
| Construction In Progress | $45,000 | $86,000 | $5,000 | $172,000 |
| Other Properties | $5,939,000 | $6,024,000 | $6,807,000 | $7,866,000 |
| Machinery Furniture Equipment | $1,076,000 | $894,000 | $987,000 | $778,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $9,860,000 | $5,811,000 | $5,962,000 | $7,901,000 |
| Work In Process | $3,094,000 | $2,130,000 | $3,537,000 | $2,992,000 |
| Raw Materials | $7,470,000 | $757,000 | $4,478,000 | $3,284,000 |
| Other Inventories | - | $494,000 | $548,000 | $500,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $13,212,000 | $11,946,000 | $6,969,000 | $-15,432,000 |
| Operating Activities | ||||
| Operating Cash Flow | $13,504,000 | $12,109,000 | $7,117,000 | $-15,098,000 |
| Cash Flow From Continuing Operating Activities | $13,504,000 | $12,109,000 | $7,117,000 | $-15,098,000 |
| Operating Gains Losses | $4,000 | $-19,000 | $-5,000 | $7,000 |
| Investing Activities | ||||
| Capital Expenditure | $-292,000 | $-163,000 | $-148,000 | $-334,000 |
| Investing Cash Flow | $-292,000 | $-143,000 | $-143,000 | $-334,000 |
| Cash Flow From Continuing Investing Activities | $-292,000 | $-143,000 | $-143,000 | $-334,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-251,000 | $0 | - | - |
| Financing Cash Flow | $6,916,000 | $5,369,000 | $-90,000 | $7,654,000 |
| Cash Flow From Continuing Financing Activities | $6,916,000 | $5,369,000 | $-90,000 | $7,654,000 |
| Net Other Financing Charges | $-67,000 | $-52,000 | $-75,000 | $-77,000 |
| Net Common Stock Issuance | $-251,000 | $0 | $0 | $7,747,000 |
| Issuance Of Capital Stock | - | - | $0 | $7,747,000 |
| Common Stock Issuance | - | - | $0 | $7,747,000 |
| Other | ||||
| Repayment Of Debt | $-12,000 | $-11,000 | $-15,000 | $-16,000 |
| Interest Paid Supplemental Data | $1,000 | $1,000 | $2,000 | $1,000 |
| End Cash Position | $64,788,000 | $44,660,000 | $27,325,000 | $20,441,000 |
| Beginning Cash Position | $44,660,000 | $27,325,000 | $20,441,000 | $28,219,000 |
| Changes In Cash | $20,128,000 | $17,335,000 | $6,884,000 | $-7,778,000 |
| Proceeds From Stock Option Exercised | $7,246,000 | $5,432,000 | $0 | $0 |
| Common Stock Payments | $-251,000 | $0 | - | - |
| Net Issuance Payments Of Debt | $-12,000 | $-11,000 | $-15,000 | $-16,000 |
| Net Long Term Debt Issuance | $-12,000 | $-11,000 | $-15,000 | $-16,000 |
| Long Term Debt Payments | $-12,000 | $-11,000 | $-15,000 | $-16,000 |
| Net PPE Purchase And Sale | $-292,000 | $-143,000 | $-143,000 | $-334,000 |
| Sale Of PPE | $0 | $20,000 | $5,000 | $0 |
| Purchase Of PPE | $-292,000 | $-163,000 | $-148,000 | $-334,000 |
| Change In Working Capital | $-8,230,000 | $3,217,000 | $4,622,000 | $-6,014,000 |
| Change In Other Working Capital | $-122,000 | $-316,000 | $-606,000 | $-396,000 |
| Change In Other Current Liabilities | $-949,000 | $-615,000 | $-519,000 | $-463,000 |
| Change In Payables And Accrued Expense | $4,111,000 | $139,000 | $2,709,000 | $112,000 |
| Change In Accrued Expense | $1,841,000 | $1,206,000 | $2,156,000 | $856,000 |
| Change In Payable | $2,270,000 | $-1,067,000 | $553,000 | $-744,000 |
| Change In Account Payable | $2,270,000 | $-1,067,000 | $553,000 | $-744,000 |
| Change In Prepaid Assets | $1,121,000 | $-45,000 | $631,000 | $-872,000 |
| Change In Inventory | $-11,635,000 | $5,333,000 | $152,000 | $-1,076,000 |
| Change In Receivables | $-756,000 | $-1,279,000 | $2,255,000 | $-3,319,000 |
| Changes In Account Receivables | $-756,000 | $-1,279,000 | $2,255,000 | $-3,319,000 |
| Other Non Cash Items | $-1,952,000 | $-3,524,000 | $15,000 | $-237,000 |
| Stock Based Compensation | $6,067,000 | $3,656,000 | $4,751,000 | $5,739,000 |
| Provisionand Write Offof Assets | $-1,217,000 | $-1,255,000 | $964,000 | $63,000 |
| Depreciation Amortization Depletion | $1,450,000 | $1,484,000 | $1,705,000 | $1,884,000 |
| Depreciation And Amortization | $1,450,000 | $1,484,000 | $1,705,000 | $1,884,000 |
| Amortization Cash Flow | $173,000 | $151,000 | $158,000 | $186,000 |
| Amortization Of Intangibles | $173,000 | $151,000 | $158,000 | $186,000 |
| Depreciation | $1,277,000 | $1,333,000 | $1,547,000 | $1,698,000 |
| Gain Loss On Sale Of PPE | $4,000 | $-19,000 | $-5,000 | $7,000 |
| Net Income From Continuing Operations | $17,382,000 | $8,550,000 | $-4,938,000 | $-16,540,000 |
| Asset Impairment Charge | - | $0 | $3,000 | $0 |
| Net Intangibles Purchase And Sale | - | - | - | - |
| Purchase Of Intangibles | - | - | - | - |
Fetched: 2026-06-15